VERAXA Biotech (NASDAQ: VRXA) is pushing forward with a strategy to integrate U.S. Food and Drug Administration-aligned New Approach Methodologies (NAMs) across its preclinical research and development programs. The company, which is developing next-generation antibody-based cancer therapies, announced the update through NEWMEDIAWIRE on October 7, 2026.
The significance of this move extends beyond a single company. By adopting NAMs, VERAXA aims to accelerate clinical advancement, reduce development costs and timelines, and significantly decrease animal testing. This approach aligns with a broader regulatory shift toward more human-relevant testing models, potentially setting a new standard for preclinical research in oncology.
VERAXA has built a panel of NAMs to characterize and de-risk its pipeline, which includes BiTAC-based T cell engagers, antibody-drug conjugates, and bispecific antibody-drug conjugates. A key demonstration of this strategy involved evaluating lead BiTAC-TCE and bsADC candidates using an ex vivo panel of 10 low-passage patient-derived xenograft models of non-small cell lung cancer. This panel required only about 10 mice in total, compared with an estimated 200 or more for comparable in vivo efficacy studies. Across the panel, the combined BiTAC consistently induced potent T cell-mediated killing, supporting the company's dual-targeting approach and showing that its NAM strategy can reduce animal use and preclinical cycle time without compromising clinical relevance.
The implications are substantial. For investors, the adoption of NAMs could mean faster progression of VERAXA's pipeline into clinical trials, lower development costs, and a reduced risk of late-stage failures due to better predictive models. For the biotech industry, it signals a growing acceptance of alternatives to traditional animal testing, which could pressure other companies to follow suit. For animal welfare advocates, it represents a tangible step toward reducing the number of animals used in research.
VERAXA was founded on scientific breakthroughs made at the European Molecular Biology Laboratory (EMBL), a world-renowned institution known for pioneering life science research. The company is rapidly advancing its pipeline of ADCs and proprietary BiTAC formats into clinical development and beyond.
To view the full press release, visit https://ibn.fm/9YRJw. The latest news and updates relating to VRXA are available in the company's newsroom at https://ibn.fm/VRXA. Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: https://IBN.ai/Disclaimer.
